Hengrui anti-tumor drug cyclophosphamide injection is approved to be listed in the United States

It is worth mentioning that only Baite International Co., Ltd in the United States has the injection approval before, and Hengrui pharmaceutical products have a large market space after being listed According to the public information, cyclophosphamide is a traditional anti-tumor drug, which is suitable for leukemia, lymphoma, metastatic and non metastatic solid tumors, etc the original research enterprise is Baite International Co., Ltd According to FDA's website, before that, only Baite International Co., Ltd and Roxane, a generic pharmaceutical company, had the approval for cyclophosphamide preparation production in the United States, and Roxane's product dosage forms were tablets and capsules After being listed, Hengrui pharmaceutical will become the first injection imitator Previously, the company said at the securities strategic meeting that the sales scale of cyclophosphamide in the United States is now more than 400 million US dollars, and it is expected that the company's products will quickly seize the product market after listing, driving the further expansion of export business Shenyin Wanguo pointed out that according to the research on the U.S market, cyclophosphamide is expected to achieve more than $100 million in revenue next year Hengrui pharmaceutical is a leading enterprise in the field of tumor medicine in China Internationalization and technological innovation are two strategic development directions of the company The company pointed out in the minutes of the exchange meeting publicly disclosed earlier that the revenue recognized for the export of the overall preparations this year is about 20-30 million yuan.